Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
108 studies found for:    Melanoma (women OR woman OR female)
Show Display Options
Rank Status Study
21 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
22 Completed Everolimus in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: everolimus
23 Suspended Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Drug: Trametinib;   Other: Laboratory Biomarker Analysis
24 Active, not recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: sargramostim
25 Suspended High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa;   Other: clinical observation
26 Recruiting Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel
27 Completed Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Genetic: protein expression analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
28 Completed Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: alvocidib
29 Completed
Has Results
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: sorafenib tosylate;   Drug: tipifarnib;   Drug: temsirolimus
30 Completed Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: temozolomide
31 Completed Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Condition: Melanoma (Skin)
Interventions: Drug: everolimus;   Drug: temozolomide;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: immunologic technique
32 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: polarized dendritic cells;   Biological: non-polarized dendritic cells
33 Recruiting A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Intervention:
34 Completed NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Condition: Melanoma
Intervention: Procedure: Sentinel Lymph Node Mapping
35 Suspended Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Leflunomide
36 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
37 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Other: Laboratory Biomarker Analysis
38 Completed Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Sargramostim
39 Completed SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: ispinesib
40 Recruiting Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: DC vaccine;   Drug: Dasatinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years